Elliot Hershberg
@ElliotHershberg
Partner @AmplifyPartners, writing https://centuryofbio.com/
Announcing Amplify Bio 🧬 I've joined Amplify Partners to help build a $200M fund dedicated to technical founders in bio. This has been part of a long evolution—from writing code as a computational biologist, to writing >200k words about this sector in The Century of Biology,…
Never ceases to blow my mind that $NVDA is worth more than *all* of the top 20 pharmas combined. We're just scratching the surface of efficiently designing—and distributing—medicines and diagnostics. There is so much left to build!
We talked to @ElliotHershberg (Partner @AmplifyPartners) about the challenges in life sciences technology. "There has been a general sentiment that you can make a huge amount of progress with new data and new technology in life sciences." "It actually turns out that it's really…
Excited to chop it up with the @tbpn gentlemen later today! 🧬
Morning. Here are our guest call-ins today: – @cpaik (Pace Capital) – @willbruey (Varda) – Joel Becker (METR) – @karimatiyeh (Ramp) – Dylan Parker (Moment) – @iplayedd1 (Consensus) – @ghita__ha (ZeroEntropy) – @elliothershberg (Amplify) See you all on the stream.
This is one of the core questions I tried to answer in my recent essay on virtual cells. If we are still far from modeling E. coli, what explains the jump right to mammalian cells? I think there are two components to the answer. First, researchers like have made a lot more…
Feels like when people talk about virtual cells they’re implicitly referring to human cells. Show me we can model metabolic perturbations in a yeast cell — scratch that, a bacterial cell! — and then I’ll pay attention to attempts to do the same in human cells. That’s why…
What Are Virtual Cells? centuryofbio.com/p/virtual-cell Two months ago, I started working on an essay to answer this question. The goal was to cover a few of the recent research results. Simple as that! Instead, I went down a rabbit hole exploring ideas around cellular simulation…
I think Royalty made another very smart deal with RevMed. One thing I consistently wonder about is why Royalty has so little competition. In a world where fast-followers keep getting faster, I'd love to see more capital available for biotechs to pursue late-stage development +…
I was in Boston this week for BIO. As a SF Biohub maximalist, I’ve got to admit: the summer vibes in Cambridge are immaculate. It’s hot and humid, but the street canopy provides some shade. People escape their stuffy brownstones to lounge in the park. Conversations about…
To replace animal testing with AI, we need MASSIVE human datasets. Today, we're thrilled to share Axiom's new data exploration tool, providing the ability to visually explore the world's largest primary human liver toxicity dataset. Built with Axiom's proprietary wetlab…
🧵1/ We @tahoe_ai just published a new post on the Tahoe blog—a story of how we used Tahoe-100M, the world’s largest drug-perturbed single-cell dataset, to find compounds that upregulate MHC-I and make tumors more visible to the immune system. Here’s how 🧬🔍👇
Awesome take by Carl June at the FDA's cell & gene therapy roundtable. Before considering trade regulations, we should look in the mirror and see what we can improve! There probably is a place for IITs in the US system.
New funds, new look, same Amplify. Announcing our $900M 6th set of funds, our first ever digital bio fund, and our new logo and site. The first (and best) investor for technical founders. amplifypartners.com/blog-posts/fun…
Exclusive: Amplify Partners has raised $200 million for its first biotech-specific fund Targeting ~20 investments of $1.5m-$10m in pre-seed/seed/Series A-stage startups. The Silicon Valley VC has also hired @ElliotHershberg as a partner: endpoints.news/amplify-raises…